Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Eli Gelfand, M.D.

Co-Author

This page shows the publications co-authored by Eli Gelfand and Christopher Cannon.
Connection Strength

1.407
  1. Myocardial infarction: contemporary management strategies. J Intern Med. 2007 Jul; 262(1):59-77.
    View in: PubMed
    Score: 0.358
  2. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol. 2006 May 16; 47(10):1919-26.
    View in: PubMed
    Score: 0.330
  3. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Investig Drugs. 2006 Mar; 15(3):307-15.
    View in: PubMed
    Score: 0.326
  4. Antibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT. Am Heart J. 2004 Feb; 147(2):202-9.
    View in: PubMed
    Score: 0.283
  5. Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients. Curr Atheroscler Rep. 2007 Nov; 9(5):359-66.
    View in: PubMed
    Score: 0.092
  6. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J. 2004 Nov; 25(22):1998-2005.
    View in: PubMed
    Score: 0.019
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.